Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pro Kidney has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is situated within 1 distinct art unit, reflecting a specific technical focus for the company's current patent efforts. The matter is being handled by a distinct examiner, MOLOYE, TITILAYO, who is the busiest examiner for the company. This relationship between the pending action, the art unit, and the examiner simplifies the current prosecution landscape.
MOLOYE, TITILAYO is responsible for the pending office action currently active for Pro Kidney. Because the company only has 1 pending action and a single distinct examiner, the prosecution profile is straightforward. Practitioners should focus on the specific requirements of the Biotechnology & Pharmaceuticals area as interpreted by this examiner. The presence of a single examiner and 1 art unit means that Pro Kidney does not currently face the challenge of coordinating across different USPTO departments, allowing for a highly specific prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOLOYE, TITILAYO | 1 | 62.2% | +48.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18876597 | SELECTED RENAL CELL POPULATIONS, CHARACTERISTICS AND USES THEREOF | MOLOYE, TITILAYO | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18876597 | SELECTED RENAL CELL POPULATIONS, CHARACTERISTICS AND USES THEREOF | MOLOYE, TITILAYO | 1632 | §103§112DP | Non-Final OA | — | Pending | Dec 18, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPro Kidney has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Titilayo Moloye has the most, with 1 of Pro Kidney's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.